Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03891628
Other study ID # PSYC412125
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 13, 2018
Est. completion date March 31, 2021

Study information

Verified date August 2021
Source University of Delaware
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the efficacy of the modified Attachment and Biobehavioral Catch-Up Intervention, adapted for use with peripartum mothers receiving medication-assisted treatment for opioid use disorder. The investigators expect that mothers who receive the modified Attachment and Biobehavioral Catch-up Intervention will show more nurturing and sensitive parenting and more adaptive physiological regulation than parents who receive a control intervention. The investigators expect that infants whose mothers receive the modified Attachment and Biobehavioral Catch-up will show better outcomes in attachment, behavior, and physiological regulation compared to infants of parents who receive the control intervention.


Description:

Peripartum mothers will be randomly assigned to receive the modified ABC intervention or the control intervention (modified DEF). Hypotheses relate to parent and child outcomes associated with the intervention. Hypothesis 1: Compared to mothers who receive the control intervention, mothers who receive the ABC intervention will show more nurturing and sensitive parenting, enhanced neural activity during parenting-relevant tasks, and more normative patterns of DNA methylation, autonomic nervous system activity, and cortisol production. Hypothesis 2: Compared to infants of mothers who receive the control intervention, infants of mothers who receive the ABC intervention will show more organized and secure attachment patterns, better behavioral regulation during stressors, more advanced social-emotional development, and more normative patterns of DNA methylation, autonomic nervous system activity, and cortisol production. Hypothesis 3: Enhanced maternal sensitivity will mediate effects of the ABC intervention on improved infant outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date March 31, 2021
Est. primary completion date March 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - In third trimester of pregnancy or up to one month postpartum - Receiving medication-assisted treatment for opioid use disorder Exclusion Criteria: - None

Study Design


Intervention

Behavioral:
Modified Attachment and Biobehavioral Catch-up
Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
Modified Developmental Education for Families
Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.

Locations

Country Name City State
United States University of Delaware Newark Delaware

Sponsors (1)

Lead Sponsor Collaborator
University of Delaware

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal sensitivity Maternal sensitivity will be coded observationally from maternal interactions with an infant simulator pre-programmed to coo and then cry. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal sensitivity Maternal sensitivity will be coded observationally from mother-infant play interactions, in which mothers will be given toys and asked to play as they normally would. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting. Infant age 3 months
Primary Maternal sensitivity Maternal sensitivity will be coded observationally from mother-infant play interactions, in which mothers will be given toys and asked to play as they normally would. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting. Infant age 6 months
Primary Maternal sensitivity Maternal sensitivity will be coded observationally from mother-infant play interactions, in which mothers will be given toys and asked to play as they normally would. Mothers will be coded for sensitivity, nurturance, intrusiveness, detachment, and positive regard, on 5 point scales from 1-Not at all characteristic to 5-Highly characteristic. Higher scores on sensitivity, nurturance, and positive regard represent more positive parenting, whereas higher scores on nurturance and detachment represent less positive parenting. Infant age 12 months
Primary Maternal methylation of µ-opioid receptor (OPRM1) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal methylation of µ-opioid receptor (OPRM1) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 3 months
Primary Maternal methylation of µ-opioid receptor (OPRM1) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 6 months
Primary Maternal methylation of µ-opioid receptor (OPRM1) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 12 months
Primary Maternal methylation of oxytocin receptor (OXTR) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal methylation of oxytocin receptor (OXTR) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 3 months
Primary Maternal methylation of oxytocin receptor (OXTR) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 6 months
Primary Maternal methylation of oxytocin receptor (OXTR) gene Maternal methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 12 months
Primary Infant methylation of µ-opioid receptor (OPRM1) gene Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 3 months
Primary Infant methylation of µ-opioid receptor (OPRM1) gene Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 6 months
Primary Infant methylation of µ-opioid receptor (OPRM1) gene Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 12 months
Primary Infant methylation of oxytocin receptor (OXTR) gene Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 3 months
Primary Infant methylation of oxytocin receptor (OXTR) gene Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 6 months
Primary Infant methylation of oxytocin receptor (OXTR) gene Infant methylation will be assessed using direct bisulfite sequencing of DNA extracted from saliva. Infant age 12 months
Primary Maternal neural activity (EEG) - Own child-other child task Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing photos of their own infants, familiar infants, and unfamiliar infants. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal neural activity (EEG) - Own child-other child task Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing photos of their own infants, familiar infants, and unfamiliar infants. Infant age 12 months
Primary Maternal neural activity (EEG) - Reward sensitivity task Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images from four categories: opioid-related images, baby pictures, positive images, and neutral images. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal neural activity (EEG) - Reward sensitivity task Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images from four categories: opioid-related images, baby pictures, positive images, and neutral images. Infant age 12 months
Primary Maternal neural activity (EEG) - Child emotion task Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images of children crying, laughing, and showing neutral expressions. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal neural activity (EEG) - Child emotion task Maternal event-related potentials will be assessed using electroencephalogram (EEG) while viewing images of children crying, laughing, and showing neutral expressions. Infant age 12 months
Primary Maternal parasympathetic nervous system activity Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal sympathetic nervous system activity Maternal sympathetic nervous system activity will be assessed using pre-ejection period. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal parasympathetic nervous system activity Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia. Infant age 3 months
Primary Maternal sympathetic nervous system activity Maternal sympathetic nervous system activity will be assessed using pre-ejection period. Infant age 3 months
Primary Maternal parasympathetic nervous system activity Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia. Infant age 6 months
Primary Maternal sympathetic nervous system activity Maternal sympathetic nervous system activity will be assessed using pre-ejection period. Infant age 6 months
Primary Maternal parasympathetic nervous system activity Maternal parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia. Infant age 12 months
Primary Maternal sympathetic nervous system activity Maternal sympathetic nervous system activity will be assessed using pre-ejection period. Infant age 12 months
Primary Infant parasympathetic nervous system activity Infant parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia. Infant age 3 months
Primary Infant sympathetic nervous system activity Infant sympathetic nervous system activity will be assessed using pre-ejection period. Infant age 3 months
Primary Infant parasympathetic nervous system activity Infant parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia. Infant age 6 months
Primary Infant sympathetic nervous system activity Infant sympathetic nervous system activity will be assessed using pre-ejection period. Infant age 6 months
Primary Infant parasympathetic nervous system activity Infant parasympathetic nervous system activity will be assessed using respiratory sinus arrhythmia. Infant age 12 months
Primary Infant sympathetic nervous system activity Infant sympathetic nervous system activity will be assessed using pre-ejection period. Infant age 12 months
Primary Maternal diurnal cortisol production Maternal diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal diurnal cortisol production Maternal diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time. Infant age 12 months
Primary Infant diurnal cortisol production Infant diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time. Infant age 3 months
Primary Infant diurnal cortisol production Infant diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time. Infant age 6 months
Primary Infant diurnal cortisol production Infant diurnal cortisol production will be assessed through salivary cortisol levels collected at wake-time and bed-time. Infant age 12 months
Primary Infant behavioral regulation - Still Face Paradigm Behavioral coding of emotion reactivity and regulation will be conducted from video recordings of the Still Face Paradigm, a mild social stressor. Infant age 6 months
Primary Infant behavioral regulation - Arm Restraint Task Behavioral coding of emotion reactivity and regulation will be conducted from video recordings of the Arm Restraint Task, a mild stressor. Infant age 12 months
Primary Infant attachment Infant attachment will be assessed using the Strange Situation. Infant age 12 months
Primary Infant cognitive development Infant cognitive development will be assessed through maternal report on the Ages and Stages Questionnaire. Infant age 3 months
Primary Infant motor development Infant motor development will be assessed through maternal report on the Ages and Stages Questionnaire. Infant age 3 months
Primary Infant social-emotional development Infant social-emotional development will be assessed through maternal report on the Ages and Stages Questionnaire: Social-Emotional. Infant age 3 months
Primary Infant cognitive development Infant cognitive development will be assessed through maternal report on the Ages and Stages Questionnaire. Infant age 6 months
Primary Infant motor development Infant motor development will be assessed through maternal report on the Ages and Stages Questionnaire. Infant age 6 months
Primary Infant social-emotional development Infant social-emotional development will be assessed through maternal report on the Ages and Stages Questionnaire: Social-Emotional. Infant age 6 months
Primary Infant cognitive development Infant cognitive development will be assessed through maternal report on the Ages and Stages Questionnaire. Infant age 12 months
Primary Infant motor development Infant motor development will be assessed through maternal report on the Ages and Stages Questionnaire. Infant age 12 months
Primary Infant social-emotional development Infant social-emotional development will be assessed through maternal report on the Ages and Stages Questionnaire: Social-Emotional. Infant age 12 months
Primary Infant social-emotional problems Infant social-emotional problems will be assessed through maternal report on the Brief Infant-Toddler Social Emotional Assessment. Infant age 12 months
Primary Maternal self-efficacy Mothers will report on their parenting self-efficacy using the Maternal Self-Efficacy Scale. Mothers will rate their self-efficacy for each of ten items (nine discrete parenting behaviors and one global parenting item) on a 4-point scale from 1-not good at all to 4-very good. Scores are summed to form a total maternal self-efficacy composite (possible range = 10-40), where higher scores indicated more maternal self-efficacy. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal self-efficacy Mothers will report on their parenting self-efficacy using the Maternal Self-Efficacy Scale. Mothers will rate their self-efficacy for each of ten items (nine discrete parenting behaviors and one global parenting item) on a 4-point scale from 1-not good at all to 4-very good. Scores are summed to form a total maternal self-efficacy composite (possible range = 10-40), where higher scores indicated more maternal self-efficacy. Infant age 12 months
Primary Maternal emotion regulation Mothers will report on their emotion regulation using the Difficulties with Emotion Regulation Scale - Short Form (DERS-SF). The DERS-SF consists of 18 items rated on a scale from 1-almost never to 5-almost always. The DERS-SF yields six subscales (strategies, non-acceptance, impulse, goals, awareness, and clarity), each of which range from 3 to 15, and one total score, which ranges from 18 to 90. Higher scores indicate greater emotion dysregulation. Pre-intervention (third trimester of gestation or up to one month postpartum)
Primary Maternal emotion regulation Mothers will report on their emotion regulation using the Difficulties with Emotion Regulation Scale - Short Form (DERS-SF). The DERS-SF consists of 18 items rated on a scale from 1-almost never to 5-almost always. The DERS-SF yields six subscales (strategies, non-acceptance, impulse, goals, awareness, and clarity), each of which range from 3 to 15, and one total score, which ranges from 18 to 90. Higher scores indicate greater emotion dysregulation. Infant age 12 months
Secondary Maternal substance use - interview The Timeline Followback Interview will be used to assess maternal use of opioids, tobacco, alcohol, marijuana, and other substances. Pre-intervention (third trimester of gestation or up to one month postpartum)
Secondary Maternal substance use - interview The Timeline Followback Interview will be used to assess maternal use of opioids, tobacco, alcohol, marijuana, and other substances. Infant age 6 months
Secondary Maternal substance use - interview The Timeline Followback Interview will be used to assess maternal use of opioids, tobacco, alcohol, marijuana, and other substances. Infant age 12 months
Secondary Maternal substance use - questionnaire Mothers will report their history of substance use using the NIDA ASSIST questionnaire. Pre-intervention (third trimester of gestation or up to one month postpartum)
Secondary Maternal substance use - questionnaire Mothers will report recent substance use using the NIDA Quick Screen questionnaire. Infant age 3 months
Secondary Maternal substance use - questionnaire Mothers will report recent substance use using the NIDA Quick Screen questionnaire. Infant age 6 months
Secondary Maternal substance use - questionnaire Mothers will report recent substance use using the NIDA Quick Screen questionnaire. Infant age 12 months
Secondary Maternal depressive symptoms Maternal depressive symptoms will be self-reported using the Beck Depression Inventory. Pre-intervention (third trimester of gestation or up to one month postpartum)
Secondary Maternal depressive symptoms Maternal depressive symptoms will be self-reported using the Beck Depression Inventory. Infant age 3 months
Secondary Maternal depressive symptoms Maternal depressive symptoms will be self-reported using the Beck Depression Inventory. Infant age 6 months
Secondary Maternal depressive symptoms Maternal depressive symptoms will be self-reported using the Beck Depression Inventory. Infant age 12 months
Secondary Infant physical growth Infant physical growth will be assessed using weight, length, and head circumference. Infant age 3 months
Secondary Infant physical growth Infant physical growth will be assessed using weight, length, and head circumference. Infant age 6 months
Secondary Infant physical growth Infant physical growth will be assessed using weight, length, and head circumference. Infant age 12 months
Secondary Maternal experiences during labor and delivery Mothers will report on their experiences during labor and delivery using the Birth Satisfaction Scale-Revised questionnaire (BSS-R). This measure consists of ten items rated on a 5-point scale from 1-Strongly Disagree to 5-Strongly Agree. The total score ranges from 10-50, where higher scores represent more birth satisfaction. Infant age 3 months
Secondary Home environment The home environment will be assessed using the Cognitive Stimulation subscale of the HOME Short Form, a combination of observation (two items) and maternal report (seven items). Observation items are binary (yes/no), and mother-report items are rated on a Likert-type scale and dichotomized. Dichotomous items are summed to form a total score (range 0-9), with higher scores indicating more cognitive stimulation. Infant age 3 months
Secondary Maternal reward responsiveness Mothers will report their reward responsiveness using the Reward Responsiveness Scale. This is an 8-item scale rated on a 4-point scale from 1-Strong Disagreement to 4-Strong Agreement. The total score ranges from 8 to 32, with higher scores representing greater reward responsiveness. Pre-intervention (third trimester of gestation or up to one month postpartum)
Secondary Maternal reward responsiveness Mothers will report their reward responsiveness using the Reward Responsiveness Scale. This is an 8-item scale rated on a 4-point scale from 1-Strong Disagreement to 4-Strong Agreement. The total score ranges from 8 to 32, with higher scores representing greater reward responsiveness. Infant age 12 months
Secondary Maternal sleep Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index. Pre-intervention (third trimester of gestation or up to one month postpartum)
Secondary Maternal sleep Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index. Infant age 3 months
Secondary Maternal sleep Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index. Infant age 6 months
Secondary Maternal sleep Mothers will report on their sleep habits using the Pittsburgh Sleep Quality Index. Infant age 12 months
Secondary Infant sleep Mothers will report on their infant's sleep habits using the Brief Infant Sleep Questionnaire. Infant age 3 months
Secondary Infant sleep Mothers will report on their infant's sleep habits using the Brief Infant Sleep Questionnaire. Infant age 6 months
Secondary Infant sleep Mothers will report on their infant's sleep habits using the Brief Infant Sleep Questionnaire. Infant age 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03950492 - Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder N/A
Completed NCT00000335 - Activity Monitoring Assessment of Opiate Withdrawal - 4 Phase 2
Active, not recruiting NCT03949764 - The Kentucky Viral Hepatitis Treatment Study Phase 4
Enrolling by invitation NCT06084221 - Fatal Overdose Review Teams - Research to Enhance Surveillance Systems N/A
Completed NCT02978417 - Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Phase 4
Withdrawn NCT03137030 - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults Phase 1
Withdrawn NCT03137017 - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults Phase 1
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT00710385 - Abuse Liability of Suboxone Versus Subutex Phase 3
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Completed NCT00218309 - Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals Phase 2
Completed NCT00067184 - Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
Terminated NCT00000243 - Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone N/A
Completed NCT00000264 - Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16 N/A
Completed NCT00000257 - Effects of Alcohol History on Effects of Nitrous Oxide - 9 N/A
Completed NCT00000279 - Novel Medications for Opiate Detoxification - 4 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000249 - Effects of Subanesthetic Concentrations of Nitrous Oxide - 1 Phase 2
Recruiting NCT04933084 - Pre-operative Education Modalities to Decrease Opioid Use N/A
Recruiting NCT03610672 - Mobile Intervention for Young Opioid Users N/A